NANO Nanobiotix SA
Financings ·
The company says cash of €110.9 million funds operations into 2029. Its first half net loss was €34.3 million, and revenue fell to €5.6 million from a year earlier that included a one-off €21.2 million gain.
We have not published a story on Nanobiotix SA yet. When there is news, it will appear here.
Nanobiotix S.A. is a late-stage clinical biotechnology company that develops physics-based nanotherapeutics. It has three platforms: the Nanoradioenhancer, designed to increase the tumor-killing effect of radiotherapy, the Nanoprimer, designed to enable extrahepatic delivery of innovative systemic therapies, and a neurological disease platform. Its most advanced candidate is JNJ-1900 (NBTXR3), which the company designed to address needs across lines of therapy in solid tumors. Janssen Pharmaceutica NV, a Johnson & Johnson company, holds a global licensing agreement for JNJ-1900 (NBTXR3) from July 2023, which the text describes as a $2.6B worldwide agreement. MD Anderson is a clinical research collaborator. The clinical pipeline prioritizes head and neck cancer in elderly patients ineligible for cisplatin-based chemotherapy, in the global randomized Phase 3 NANORAY-312 study sponsored by J&J. Other studies include the Phase 1b LUMIRAY study in head and neck cancer, the randomized Phase 2 CONVERGE study in inoperable Stage 3 lung cancer, and a randomized Phase 2/3 in soft tissue sarcoma. The Nanoprimer platform is at the preclinical stage and the neurological platform at the discovery stage.
| Product or program | What it is | Stage |
|---|---|---|
| JNJ-1900 (NBTXR3) | Nanoparticle designed to increase the tumor-killing effect of radiotherapy | Phase 3 (NANORAY-312) |
| Nanoprimer platform (Curadigm) | Lipid nanoparticles that temporarily occupy liver pathways to enable drug delivery | preclinical |
| OOcuity neurological platform | Nanoparticles designed to interact with neuronal networks | discovery |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | €32.6 million | -€7.2 million |
| Research and development | €23.1 million | €40.5 million |
| Net income (loss) | -€24.0 million | -€68.1 million |
| Cash from operations | -€33.4 million | -€19.6 million |
| Cash and equivalents | €52.8 million | €49.7 million |
Nanobiotix SA trades under the ticker NANO on EURONEXT.
Nanobiotix SA is listed on EURONEXT. Our directory also records these other listings: DUS:5NR; FWB:5NR; GETTEX:5NR; HAM:5NR; HAN:5NR; LS:A1J7EB; LSE:0QAV; LSX:A1J7EB; MUN:5NR; NASDAQ:NBTX; SWB:5NR; TRADEGATE:5NR; XETR:5NR.
The SEC Central Index Key (CIK) for Nanobiotix SA is 1760854. Its filings are on SEC EDGAR.
48,410,068 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-31.
Our directory records Nanobiotix SA under France.
Our directory classifies Nanobiotix SA as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Nanobiotix SA is FR0011341205.
aibio.space lists Nanobiotix SA among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as I0.
Nanobiotix S.A. is a late-stage clinical biotechnology company that develops physics-based nanotherapeutics. It has three platforms: the Nanoradioenhancer, designed to increase the tumor-killing effect of radiotherapy, the Nanoprimer, designed to enable extrahepatic delivery of innovative systemic therapies, and a neurological disease platform.
JNJ-1900 (NBTXR3): Nanoparticle designed to increase the tumor-killing effect of radiotherapy Stage: Phase 3 (NANORAY-312).
Nanoprimer platform (Curadigm): Lipid nanoparticles that temporarily occupy liver pathways to enable drug delivery Stage: preclinical.
Our latest story on Nanobiotix SA, dated Sep 24, 2026: "Nanobiotix reports €110.9 million cash after ~€86 million follow-on, runway into 2029". The company says cash of €110.9 million funds operations into 2029. Its first half net loss was €34.3 million, and revenue fell to €5.6 million from a year earlier that included a one-off €21.2 million gain. Source.
Our latest financing story, dated Sep 24, 2026: "Nanobiotix reports €110.9 million cash after ~€86 million follow-on, runway into 2029". The company says cash of €110.9 million funds operations into 2029. Its first half net loss was €34.3 million, and revenue fell to €5.6 million from a year earlier that included a one-off €21.2 million gain. Source.
From our story of Sep 24, 2026: The company says cash should fund operations into 2029 on its current plan. Source.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio